NCT05909943

Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Tianjin Medical University General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Rucotinib is an oral inhibitor of JAK1 and JAK2 tyrosine kinases. It may benefit some patients with NMOSD due to the important role of JAK/STAT signaling pathway in the pathogenesis of NMOSD. Clincial trials may be needed to observe its efficacy and safety.

Conditions

• Neuromyelitis Optica Spectrum Disorder Relapse

Interventions

Type	Name	Description
DRUG	Ruxolitinib	Treatment with ruxolitinib will be initiated in an initial dose regimen of 5-10 mg twice daily. Two months later, the dose of ruxolitinib will be increased to 10-15 mg twice daily.

Timeline

• Start date: 2024-06-01
• Primary completion: 2026-02-01
• Completion: 2026-08-01
• First posted: 2023-06-18
• Last updated: 2023-06-18

Locations

1 site across 1 country: China